Notably, in vivo experiments with PARPi-resistant ID8 TP53-/-/BRCA2-/- syngeneic models confirmed that both single EHMTi and combined EHMTi/PARPi treatments significantly reduced tumor growth, with effects partially dependent on CD8 + T cells. This evidence concerns the gene CD8A and neoplasm.